Search
Bromazepam
go.drugbank.com/drugs/DB01558ApprovedIllicitIt is a intermediate-acting benzodiazepine. … One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingProducts: BROMAZEPAM N&P, BROMAZEPAM EGEnoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalEnoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.
Mixtures: ENOXAPARINA SODICA 40 MG JERINGAS PRELLENADASProducts: NOXARIN® 40 MG/04 ML, ENOXPAR®INYECTABLE 40 MG /0.4 MLCloxazolam
go.drugbank.com/drugs/DB01553ExperimentalCloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. … The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety.
Categories: Heterocyclic Compounds, 2-RingProducts: OLCADIL ® 4 MG COMPRIMIDOS, OLCADIL ® 2 MG COMPRIMIDOSGadodiamide
go.drugbank.com/drugs/DB00225ApprovedInvestigationalGadodiamide is a linear, non-ionic gadolinium-based contrast agent (GBCA) that is used in magnetic resonance imaging (MRI) procedures to assist in the visualization of blood vessels. … [A263086,A263091] GBCAs constitute the largest group of MR agents, and they are thought to be safer than nonionic iodinated contrast agents.
Categories: Compounds used in a research, industrial, or household settingProducts: OMNISCAN® INYECTABLE, OMNISCAN INJECTION 0.5MMOL/ML-10ML IN GLASS VIALDurvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigationalDurvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. … [A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: IMFINZI® 50 MG/ML CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN, IMFINZI 120 MG/2.4 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETRanolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsProducts: RANEXICOR ® 500, RANEXICOR ® 1000Sitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalSitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256 … The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255].
Mixtures: SITAGLIPTIN E METFORMINA GALENICUM, SITAGLIPTIN E METFORMINA GALENICUMCategories: Drugs Used in Diabetes, Cytochrome P-450 SubstratesClodronic acid
go.drugbank.com/drugs/DB00720ApprovedInvestigationalVet approvedClodronic acid is a first generation bisphosphonate similar to [etidronic acid] and [tiludronic acid]. … [A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.
Products: ACIDO CLODRONICO EG, BONEFOS 800 MG TABLET, 60 ADETDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigational[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … [A261271] Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [venlafaxine].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: O-desmethylvenlafaxine